BioGene Therapeutics Welcomes Dr. Deepak Sampath, PhD. to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the...
Brain
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been...
Result of General Meeting
November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the...
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints CNSide CSF Assay influenced clinical...
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad...
Telerehabilitation Systems Market to Expand by USD 532.9 Million (2024-2028), Rising Chronic Disease Cases Driving Revenue, AI Impacting Market Trends – Technavio
NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global telerehabilitation systems market...
Brooks Rehabilitation, Nemours Children’s Health, Wolfson Children’s Hospital and UF Health Jacksonville Partner to Enhance Pediatric Care
JACKSONVILLE, Fla., Nov. 21, 2024 /PRNewswire/ -- By combining resources and expertise, Brooks Rehabilitation, Nemours Children's Health, Jacksonville, Wolfson Children's...
Aires Tech Showcases Advanced Technology at UFC Performance Institute with “Next Frontier of UFC Training and Performance” Symposium
Symposium gathered top fighters, neuroscientists, and media together in New York City on eve of UFC 309 UFC Performance Institute leader,...
Space-Grown Brain Organoids Help Advance New Neurological Treatment
Startup Leverages ISS National Lab to Test Viral Vector That Delivers Gene Therapy KENNEDY SPACE CENTER, Fla., Nov. 21, 2024...
New York-Based Cause of a Kind Partners with BEST Connections to Launch App Suite for Cognitive Health
NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Cause of a Kind, an award-winning leader in software and web development, has partnered...
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on...
BioGene Therapeutics Welcomes Professor Mirela Delibegovic, FRSE to Its Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the...
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in...
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
Reductions also seen in comorbid anxiety and depression symptomsBURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay...
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company...
ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS)
Company is evaluating IMSB301 in a Phase 1 clinical trial in healthy volunteers and plans to move rapidly into Phase...
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in...
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the...
Head：China makes collaborative efforts in healing people with mental disorders with AI
BEIJING, Nov. 20, 2024 /PRNewswire/ -- After a long day at work, Ni Beiyue sits in front of his computer at home,...
Embr Labs Named to Fast Company’s Fourth Annual List of The Next Big Things in Tech
List Recognizes Groundbreaking Advancements Redefining the Way We Work and Live BOSTON, Nov. 19, 2024 /PRNewswire/ -- Embr Labs, the...